Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Leukemia 9Leukemia, Myeloid, Acute 8Burkitt Lymphoma 8Recurrence 4Leukemia, Biphenotypic, Acute 4Myelodysplastic Syndromes 3Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Down Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Immunoproliferative Disorders 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 8Rituximab 7fludarabine 6dacetuzumab 6fludarabine phosphate 5blinatumomab 4Bortezomib 4ibrutinib 3Melphalan 3Lenalidomide 3Ifosfamide 3Etoposide 3Dexamethasone 3Bendamustine Hydrochloride 3AP 1903 reagent 3ponatinib 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoproliferative Disorders × asparaginase erwinia chrysanthemi recombinant × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡